ERBB2


Also found in: Dictionary, Encyclopedia.
Related to ERBB2: ERBB3, HER2, EGFR

ERBB2

A gene on chromosome 17q11.2-q12 that encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ERBB2 has no ligand-binding domain and thus cannot bind growth factors; it does, however, bind to other ligand-bound EGF receptor family members, forming a heterodimer, stabilising ligand binding and enhancing kinase-mediated activation of downstream signalling pathways (e.g., those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase).

Molecular pathology
ERBB2 amplification and overexpression commonly occurs in breast and ovarian cancers.
References in periodicals archive ?
Other significantly mutated genes included lysine (K)--specific methyltransferase 2C (KMT2C), ataxia telangiectasia mutation (ATM), FAT atypical cadherin 1 (FAT1), CREB-binding protein (CREBBP), ERBB2, spectrin alpha non-erythrocytic 1 (SPTAN1), and lysine (K)--specific methyltransferase 2A (KMT2A), which were involved in the regulation of cell proliferation, differentiation, and genetic stability.
The researchers found that activating the ERBB2 pathway triggered a cascading series of cellular events by which cochlear support cells began to proliferate and start the process of activating other neighboring stem cells to become new sensory hair cells.
In 2012, The Cancer Genome Atlas (TCGA) Network published the most comprehensive systematic molecular characterization of CRC to date, revealing genomic amplifications or mutations of the tyrosine kinase-encoding gene ERBB2 in 7% of colorectal tumors, suggesting a novel potential therapeutic target for this cancer [226].
Hynes, "ErbB2 potentiates breast tumor proliferation through modulation of [p27.sup.Kip1]-Cdk2 complex formation: receptor overexpression does not determine growth dependency," Molecular and Cellular Biology, vol.
CTCs were isolated by use of the immunomagnetic AdnaTest EMT-2/StemCellSelect[TM], targeting EPCAM, EGFR, and ERBB2. The resulting cell lysate was stored at -80[degrees]C until further use applying the AdnaTest EMT-2/StemCellDetect[TM] (both QIAGEN) according to the manufacturer's instructions (130122 EN).
Our review of the Catalogue of Somatic Mutations in Cancer (COSMIC) database identified the COSMIC identifier numbers of the following seven genes: EGFR (ENST00000275493), KRAS (ENST00000256078), PIK3CA (ENST00000263967), BRAF (ENST00000288602), ERBB2 (ENST00000269571), NRAS (ENST00000369535), and BIM (ENST_00000393256).
Two clusters of more correlated proteins were present: cluster 1: SCF, OPG, ERBB2, SEZ6L, ESM-1, and FGF-BP1; cluster 2: HGF, TNFSF14, Furin, IL-6, FGF-21, and TNFSF10.
The gene encoding ERBB2 was invalidated in HEK293 cells using CRISPR/Cas9 genome editing.
The molecular profiles of the main two types of ovarian cancer are different: While the majority of high-grade serous ovarian tumors are characterized by TP53 mutations, the low-grade carcinomas are characterized by a variety of mutations, including KRAS, BRAF, ERBB2, CTNNB1, and BCL2 mutations.
Furthermore, ERBB2 is a transmembrane receptor protein with tyrosine kinase activity and is involved in proliferation, differentiation, migration, adhesion, and apoptosis (6).
A549 cells exhibited maximum phosphorylation of EGFR at 24 h after combined treatment (Figures 2(a) and S1C), while phosphorylation of ErbB2 was increased by either TGF-[beta] or hypoxia/reoxygenation alone without a significant additive increase after combined treatment.